Clene Inc. Reports Net Loss of $36.9 Million for Q2 2023

Clene Inc.(CLNN), a prominent bi opharmaceutical company, has unveiled its financial performance for the second quarter of 2023, disclosing a net loss of $36.9 million. Despite facing operational hurdles, the company managed to generate $269,000 in revenue during the same period.

Net Loss of $36.9 Million Amidst Operating Challenges

Clene Inc. reported a net loss of $36.9 million for the second quarter of 2023. This loss was primarily attributed to operational expenses, including research and development costs, as well as general and administrative expenditures. The company faced challenges in managing its operating expenses while striving to advance its innovative initiatives in the biopharmaceutical sector.

Revenue of $269,000 Reflects Resilience